The safety & efficacy of Emgality (120mg after an initial loading dose of 240mg) is evaluated in three P-III studies EVOLVE-1- EVOlVE-2 and REGAIN study in comparison with PBO in 2500+ patients with episodic & chronic migraine respectively
Collective Results: mean change from baseline (-4.7- -4.3 & -4.8 vs -2.8- -2.3 &-2.7 days); Up to 3 in 5 patients achieved 50% reduction in migraine headache days (MHDs)/mos. (62%-59% vs 39%- 36%); >1 in 3 patients achieved 75% reduction in MHDs (39%-34% vs 19%-18%); Up to 1 in 7 patients achieved a 100% reduction in MHDs (16%- 12% vs 6%-6%); 50% reduction in MHDs (28% vs 15%) respectively
Emgality (SC) is a mAb targeting CGRP and inhibits its biological activity and is indicated for the prevention of migraine in adults with at least 4 migraine days per month in Canada
Click here to read full press release/ article
Ref: PRNewswire | Image: Eli Lilly
